Haemonetics Corporation $HAE Shares Sold by Riverwater Partners LLC

Riverwater Partners LLC trimmed its holdings in Haemonetics Corporation (NYSE:HAE) by 42.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,780 shares of the medical instruments supplier’s stock after selling 19,143 shares during the period. Riverwater Partners LLC owned 0.05% of Haemonetics worth $1,257,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new stake in Haemonetics in the third quarter valued at approximately $2,284,000. QV Investors Inc. grew its stake in shares of Haemonetics by 51.5% during the 3rd quarter. QV Investors Inc. now owns 21,870 shares of the medical instruments supplier’s stock valued at $1,066,000 after buying an additional 7,430 shares during the period. Verdence Capital Advisors LLC increased its holdings in shares of Haemonetics by 31.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 8,200 shares of the medical instruments supplier’s stock worth $420,000 after buying an additional 1,984 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Haemonetics in the 3rd quarter worth $334,000. Finally, Versant Capital Management Inc boosted its holdings in Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HAE shares. BTIG Research restated a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a report on Friday, January 9th. JPMorgan Chase & Co. lifted their price target on shares of Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research report on Friday, December 12th. Raymond James Financial reissued an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Citigroup reduced their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Finally, Barrington Research increased their price target on Haemonetics from $90.00 to $93.00 and gave the company an “outperform” rating in a report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $84.40.

Haemonetics Stock Down 0.6%

Shares of Haemonetics stock opened at $68.43 on Tuesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32. The business has a 50-day moving average of $79.22 and a 200-day moving average of $65.62. The company has a market capitalization of $3.20 billion, a PE ratio of 20.01, a P/E/G ratio of 1.43 and a beta of 0.29.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.